CN
Product Service Monitoring BGI´s Pan-Cancer+Discovery (ctDNA)
BGI´s Pan-Cancer+Discovery (ctDNA)
Suitable for the personalized diagnosis and treatment of most solid cancers (except brain cancers). It provides an interpretation of targeted drugs, immunotherapy, chemotherapy drugs and genetic risks by detecting 688 genes associated with solid cancers in peripheral blood samples (ctDNA).
Product features
Scope of the test
Suitable for

    Patients with solid cancers who wish to undergo genetic risk assessment and gain comprehensive information on the use of targeted, immunological, and chemotherapy drugs

    Patients with solid cancers who wish to be monitored

Sample requirements

    ≥10mL of peripheral blood

Customer Service:

+1 866 301 0097

Service Time:7*24

Language:English

E-mail: info@bgi.com

Copyright © BGI 2022. All Rights Reserved. Guangdong ICP Registration No. 16021117